Alpha Therapeutic Corp. v. Home Ins. Co.

109 Cal. Rptr. 2d 698, 90 Cal. App. 4th 1330
CourtCalifornia Court of Appeal
DecidedMarch 13, 2002
DocketB134257, B135081, B138225, B138843
StatusPublished
Cited by2 cases

This text of 109 Cal. Rptr. 2d 698 (Alpha Therapeutic Corp. v. Home Ins. Co.) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Alpha Therapeutic Corp. v. Home Ins. Co., 109 Cal. Rptr. 2d 698, 90 Cal. App. 4th 1330 (Cal. Ct. App. 2002).

Opinion

109 Cal.Rptr.2d 698 (2001)
90 Cal.App.4th 1330

ALPHA THERAPEUTIC CORPORATION, Plaintiff and Appellant,
v.
The HOME INSURANCE COMPANY et al., Defendants and Respondents.
Alpha Therapeutic Corporation, Plaintiff and Appellant,
v.
Associated International Insurance Company, Defendant and Appellant;
Transcontinental Insurance Company et al., Defendants and Respondents.
Alpha Therapeutic Corporation, Plaintiff and Appellant,
v.
Topa Insurance Company, Defendant and Respondent.
Alpha Therapeutic Corporation, Plaintiff and Appellant,
v.
Associated International Insurance Company, Defendant and Respondent.

Nos. B134257, B135081, B138225, B138843.

Court of Appeal, Second District, Division Two.

July 25, 2001.
Review Granted October 17, 2001.
Review Dismissed March 13, 2002.

*700 Troop Steuber Pasich Reddick & Tobey, Kirk A. Pasich, Catherine L. Rivard, Cassandra C. Shivers, Los Angeles; Heller Ehrman White & McAuliffe, Nancy Sher Cohen, Reynold L. Siemens and Carlyle W. Hall III, Los Angeles, for Plaintiff and Appellant Alpha Therapeutic Corporation.

Harrington, Foxx, Dubrow & Canter, Mark W. Flory, Nancy J. Mindel and Angela Lui Walsh, Los Angeles, for Defendant, Respondent and Appellant Associated International Insurance Company.

Kroll, Rubin & Fiorella, James D. Otto and Christine A. Roney, Los Angeles, for Defendant and Respondent The Home Insurance Company.

Ross, Dixon & Bell, Alec M. Barinholtz, Irvine, Rebecca L. Ross, Chicago, IL, Charles I. Hadden, Richard J. Pratt and Jodi L. Cleesattle, Washington, for Defendants and Respondents Transcontinental Insurance Company, London Guarantee and Accident Company of New York and Harbor Insurance Company.

Lord, Bissell & Brook and Jeri Rouse Looney, Los Angeles, for Defendant and Respondent Transport Indemnity Corporation.

No appearance for Defendant and Respondent Topa Insurance Company.

Certified for Partial Publication.[*]

*699 TODD, J.

Alpha Therapeutic Corporation appeals the grant of summary judgment against it on claims to establish coverage for defense and indemnity obligations under successive excess general liability policies issued over a seven-year period. Coverage was denied and summary judgment granted based on the trial court's application of the "anti-stacking" principle, as enunciated in FMC Corp. v. Plaisted & Companies (1998) 61 Cal.App.4th 1132, 72 Cal.Rptr.2d 467 (FMC), limiting recovery to a single year's total policy limits, as well as application of the concept of "qualified time on the risk," which resulted in the single year's total limit being allocated over the seven years of coverage.

We conclude the "anti-stacking" rule was misapplied and the undisputed facts were insufficient to establish that the excess carriers could have no obligation to indemnify Alpha. The judgments will be reversed, and the matter remanded for further proceedings consistent with this opinion.

FACTUAL AND PROCEDURAL BACKGROUND

Alpha Therapeutic Corporation was in the business of processing and distributing blood factor concentrates, a substance separated from human plasma which provides reliable and measurable doses of clotting factors used in the treatment of hemophiliacs. Alpha, along with other processors of the factor concentrates, was sued by thousands of hemophiliacs who had used the factor concentrates between 1978 and 1985 and claimed HIV infection from their use during that period.[1]

*701 The physiological phenomenon of HIV infection is that within a short period after infection, the body develops antibodies to the virus. The "assault on the immune system is immediate. The victim suffers from a sudden and serious decline in the number of white blood cells. There is no latency period.... HIV infection [has] ... a constant and detrimental effect on the infected person's hemic and lymphatic systems from the moment of infection." (Bragdon v. Abbott (1998) 524 U.S. 624, 635-637, 118 S.Ct. 2196, 141 L.Ed.2d 540.) The disease process "follows a predictable and, as of today, an unalterable course." (Id. at p. 633,118 S.Ct. 2196.)

Hemophiliacs became infected with HIV from the use of factor concentrates as early as 1978, but there was no licensed test for the presence of antibodies before March 1985. Since 1985 it has been possible to diagnose HIV infection after seroconversion, the point at which antibodies reach a detectable level. Still, there is no test for the actual date of infection and it has not been feasible to determine an individual claimant's actual date of infection because generally no blood samples were retained which might provide evidence of that date and symptoms of infection are not always distinct from those of other illnesses, such as the flu. Furthermore, an infected person may test negative for the presence of HIV antibodies for a period of time after infection. Alpha contends, however, that epidemiological studies have been conducted which provide information concerning the approximate number of HIV seroconversions among the hemophiliac community at any given time between 1978 and 1985.[2]

The Policies

Facing liability for thousands of AIDS-related claims, Alpha sued its insurers to establish their respective defense and indemnity obligations under successive primary and excess general liability polices issued to Alpha for the years 1978 to 1985, sometimes referred to as "Policy Years" 1 through 7. The respondents in these consolidated appeals are excess insurers that collectively provided over half of Alpha's seven-year total "per occurrence" limits. In general these excess insurers provided coverage for sums Alpha became obligated to pay because of "bodily injury" during the policy period, caused by an "occurrence," to the extent those sums exceeded the limits of the underlying primary and any lower-level excess liability coverage.

The Parties' Stipulations

Alpha's suit originally involved additional insurers and issues. After some parties were dismissed,[3] the remaining parties entered into a number of stipulations to facilitate a trial limited to the issue of the proper allocation of the excess insurers' indemnity obligations.

It was stipulated that all of the policies were "triggered," that is, potentially responsible *702 to indemnify the insured, under the "continuous injury" coverage trigger theory adopted in Montrose Chemical Corp. v. Admiral Ins. Co. (1995) 10 Cal.4th 645, 42 Cal.Rptr.2d 324, 913 P.2d 878 (Montrose).

The parties further stipulated that Alpha's processing, marketing, and sale of factor concentrates allegedly contaminated with HIV constituted a single "occurrence" within the meaning of the policies, that the occurrence continued in each of the seven policy years and caused "bodily injury" during each of the policy years, and that each bodily injury continued from infection1 to the death of the individual or to the present.

The parties stipulated to the amount that Alpha had already paid or agreed to pay for settlements or judgments of AIDS-related claims. The full amount of Alpha's liability to the bodily injury claimants could not at that time be determined because Alpha faced liability as a defendant in a number of separate lawsuits and for additional contributions to a class action settlement.[4]

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
109 Cal. Rptr. 2d 698, 90 Cal. App. 4th 1330, Counsel Stack Legal Research, https://law.counselstack.com/opinion/alpha-therapeutic-corp-v-home-ins-co-calctapp-2002.